Wingfield [5] applied radiomics features to predict the expression levels of CD44 and CD133 in lower-grade gliomas; In the training and validation sets, the model yielded AUCs of 0.912 and 0.805, respectively, in the CD44 model; 0.912 and 0.816, respectively, in the CD133 model. The gene discussed is PROM1; the disease is glioma.